Cargando…

The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults

Bacterial central nervous system (CNS) infections are serious and carry significant morbidity and mortality. They encompass many syndromes, the most common being meningitis, which may occur spontaneously or as a consequence of neurosurgical procedures. Many classes of antimicrobials are in clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Haddad, Nicholas, Carr, Maddie, Balian, Steve, Lannin, James, Kim, Yuri, Toth, Courtney, Jarvis, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774927/
https://www.ncbi.nlm.nih.gov/pubmed/36551500
http://dx.doi.org/10.3390/antibiotics11121843
_version_ 1784855518969331712
author Haddad, Nicholas
Carr, Maddie
Balian, Steve
Lannin, James
Kim, Yuri
Toth, Courtney
Jarvis, Jennifer
author_facet Haddad, Nicholas
Carr, Maddie
Balian, Steve
Lannin, James
Kim, Yuri
Toth, Courtney
Jarvis, Jennifer
author_sort Haddad, Nicholas
collection PubMed
description Bacterial central nervous system (CNS) infections are serious and carry significant morbidity and mortality. They encompass many syndromes, the most common being meningitis, which may occur spontaneously or as a consequence of neurosurgical procedures. Many classes of antimicrobials are in clinical use for therapy of CNS infections, some with established roles and indications, others with experimental reporting based on case studies or small series. This review delves into the specifics of the commonly utilized antibacterial agents, updating their therapeutic use in CNS infections from the pharmacokinetic and pharmacodynamic perspectives, with a focus on the optimization of dosing and route of administration that have been described to achieve good clinical outcomes. We also provide a concise synopsis regarding the most focused, clinically relevant information as pertains to each class and subclass of antimicrobial therapeutics. CNS infection morbidity and mortality remain high, and aggressive management is critical in ensuring favorable patient outcomes while averting toxicity and upholding patient safety.
format Online
Article
Text
id pubmed-9774927
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97749272022-12-23 The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults Haddad, Nicholas Carr, Maddie Balian, Steve Lannin, James Kim, Yuri Toth, Courtney Jarvis, Jennifer Antibiotics (Basel) Review Bacterial central nervous system (CNS) infections are serious and carry significant morbidity and mortality. They encompass many syndromes, the most common being meningitis, which may occur spontaneously or as a consequence of neurosurgical procedures. Many classes of antimicrobials are in clinical use for therapy of CNS infections, some with established roles and indications, others with experimental reporting based on case studies or small series. This review delves into the specifics of the commonly utilized antibacterial agents, updating their therapeutic use in CNS infections from the pharmacokinetic and pharmacodynamic perspectives, with a focus on the optimization of dosing and route of administration that have been described to achieve good clinical outcomes. We also provide a concise synopsis regarding the most focused, clinically relevant information as pertains to each class and subclass of antimicrobial therapeutics. CNS infection morbidity and mortality remain high, and aggressive management is critical in ensuring favorable patient outcomes while averting toxicity and upholding patient safety. MDPI 2022-12-19 /pmc/articles/PMC9774927/ /pubmed/36551500 http://dx.doi.org/10.3390/antibiotics11121843 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Haddad, Nicholas
Carr, Maddie
Balian, Steve
Lannin, James
Kim, Yuri
Toth, Courtney
Jarvis, Jennifer
The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults
title The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults
title_full The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults
title_fullStr The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults
title_full_unstemmed The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults
title_short The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults
title_sort blood–brain barrier and pharmacokinetic/pharmacodynamic optimization of antibiotics for the treatment of central nervous system infections in adults
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774927/
https://www.ncbi.nlm.nih.gov/pubmed/36551500
http://dx.doi.org/10.3390/antibiotics11121843
work_keys_str_mv AT haddadnicholas thebloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults
AT carrmaddie thebloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults
AT baliansteve thebloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults
AT lanninjames thebloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults
AT kimyuri thebloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults
AT tothcourtney thebloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults
AT jarvisjennifer thebloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults
AT haddadnicholas bloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults
AT carrmaddie bloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults
AT baliansteve bloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults
AT lanninjames bloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults
AT kimyuri bloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults
AT tothcourtney bloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults
AT jarvisjennifer bloodbrainbarrierandpharmacokineticpharmacodynamicoptimizationofantibioticsforthetreatmentofcentralnervoussysteminfectionsinadults